Novo Nordisk Secures EU Approval for Catalent Plant Acquisition: What It Means for the Pharma Giant

Novo Nordisk has recently achieved a significant milestone in its expansion strategy, as the European Union has granted approval for its acquisition of manufacturing plants from Catalent Inc. This decision marks a pivotal moment for the Danish pharmaceutical powerhouse, which is chiefly renowned for its leadership in diabetes and obesity care solutions.

Continue reading